Predicting stage ypT0–1N0 for nonradical management in patients with middle or low rectal cancer who undergo neoadjuvant chemoradiotherapy: a retrospective cohort study

Jeehye Lee¹, In Jun Yang¹, Jung Wook Suh¹, Hong-min Ahn¹, Heung-Kwon Oh¹, Duck-Woo Kim¹, Young-Hoon Kim², Kyoung Ho Lee², Sung-Bum Kang¹

¹Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
²Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

INTRODUCTION

Patients with a good response to concurrent chemoradiotherapy (CCRT) may have good oncological outcomes [1-3]. This can potentially allow for long-term conservative approaches, such as local excision or watchful waiting, which avoid the risks of

Purpose: It is important to discover predictive factors that can identify rectal cancer patients who will respond well to neoadjuvant concurrent chemoradiotherapy (CCRT) to develop management strategies, preserve sphincter and avoid overtreatment. This study explored clinical factors that would predict the adequacy of nonradical management after CCRT in patients with middle or low rectal cancer.

Methods: We retrospectively evaluated 447 patients with middle or low rectal cancer who were treated with curative surgery after neoadjuvant CCRT between January 2010 and December 2019. The good response group comprised patients with stages ypT0–1N0 on resection after CCRT; the remaining patients were included in the poor response group.

Results: Of 447 patients (mean age, 60.37 ± 11.85 years), 108 (24.2%) had ypT0–1N0 (71.3% with ypT0N0, 4.6% with ypTisN0, and 24.1% with ypT1N0). Overall, 19 patients with cT1–2 (50.0% vs. 21.8% with cT3–4, P < 0.001), 22 with well-differentiated tumors (51.2% vs. 21.3% with moderately/poorly differentiated tumors, P < 0.001), 16 with fungating tumors (47.1% vs. 22.3% with other types, P = 0.001), and 66 with anterior/posterior circumference direction (28.9% vs. 19.2% with lateral/encircling direction, P = 0.016) had stage ypT0–1N0. On multivariable analysis, cT1–2 (P = 0.021) and well differentiation (P = 0.001) were independent predictors of ypT0–1N0. Fungating tumors were not significantly associated with ypT0–1N0 (P = 0.054).

Conclusion: Stage cT1–2 and well differentiation are predictors of ypT0–1N0, while fungating tumors could be considered clinically meaningful, possibly identifying candidates for nonradical treatment post-CCRT.

[Ann Surg Treat Res 2022;103(1):32-39]

Key Words: Chemoradiotherapy, Colorectal neoplasms, General surgery, Rectal neoplasms
surgical complications, including the need for a stoma [4]. In treating patients with low rectal cancer, preserving the anal sphincter and improving the quality of life via neoadjuvant CCRT are critical goals. However, the current standard treatment for locally advanced rectal cancer is neoadjuvant CCRT, followed by total mesorectal excision [5].

Several researchers have investigated the association between clinical parameters and pathological tumor response in patients with locally advanced rectal cancer. Tumor size [6,7], movability [6], and circumferential extent [8] as well as T stage. N stage, and histological grade [9] have been found to be predictive factors of responses to preoperative CCRT in these patients. Other studies have also found that a low CEA level, high hemoglobin level, and low neutrophil-to-lymphocyte ratio are predictors of good tumor response to CCRT [10-13].

The European Society for Medical Oncology and National Comprehensive Cancer Network guidelines, which were based on multidisciplinary expert opinions, suggested that fragile patients who are at high risk of adverse events following surgery may instead suffice with the watch and wait method if clinical complete response is achieved as determined by digital rectal examination (DRE), rectoscopic biopsy, and/or MRI [14,15]. There have been numerous efforts to identify predictive factors for good responses to CCRT; however, the use of these variables, which involve maintaining certain blood cell counts or serum marker levels during treatment, has been difficult to apply clinically [16-20]. Therefore, there remains a need to identify factors that can be easily evaluated in clinical practice. In particular, predictors of achieving ypT0–1 stage, which is suitable for local excision or “watch and wait,” would help in supporting the current clinical trend of preserving the sphincter and avoiding overtreatment in rectal cancer.

This study aimed to identify and clinically assess factors that are predictive of achieving stage ypT0–1N0 after neoadjuvant CCRT in patients with middle or low rectal cancer, while focusing on information that clinicians are most familiar with, especially MRIs.

**METHODS**

The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital (No. B-2108/702-103). Owing to the study’s retrospective nature, the requirement for informed consent was waived.

**Study population**

Between January 2010 and December 2019, 523 patients with mid to low rectal cancer, characterized by an inferior margin located at a distance below 10 cm from the anal verge, underwent surgery followed by neoadjuvant CCRT at a single center [14,21]. Among these patients, we excluded 23 with a history of another cancer to avoid potential interference [22,23]. 3 with perforation. 3 with stents inserted for obstruction, 20 with distant metastases, and 27 lacking MRIs pre- or post-CCRT. Patients who underwent curative-intent surgery 6–8 weeks following completion of neoadjuvant CCRT at our hospital were included. Ultimately, a total of 447 patients with pathologically confirmed middle or low rectal cancer who received neoadjuvant CCRT were identified and retrospectively analyzed (Fig. 1).

Patients with stage ypTisN0 or T1N0 as well as those who achieved a pathological complete response (pCR) after neoadjuvant CCRT and surgical resection (108 patients) were classified under the good response group, whereas the remaining patients (339 patients) were included in the poor response group (Fig. 1).

**Data collection**

All data were retrospectively analyzed using a prospectively collected database that contained patient demographics, including age, sex, height, weight, body mass index (BMI), American Society of Anesthesiologists (ASA) physical status (PS) classification, past medical history (including endoscopic procedures), CEA level, endoscopic information (anterior segment and type of tumor), pathological findings, and radiological findings. The normal range of CEA was defined as ≤5 ng/mL.

All surgical procedures were performed by surgeons who were well-experienced in both open and laparoscopic total mesorectal excision for low rectal cancer. The decision to administer neoadjuvant treatment was based on the tumor stage. Patients with T3, T4, or positive nodes without distant metastases received neoadjuvant CCRT [23]. Those with T2 low rectal cancer for whom sphincter preservation was planned also received neoadjuvant CCRT [24,25].

Patients were injected with antispasmodics (hyoscine...
butylbromide) intravenously prior to MRI. Each patient was placed in the recumbent position, and 2 syringes, each filled with 50 mL of ultrasonic jelly, were injected into the anus using a catheter, while removing air as much as possible. Next, the patient was placed in the supine position, and the image was acquired using a Philips INGENIA 3.0T (Philips Medical System, Eindhoven, Netherlands). Dedicated abdominal radiologists interpreted the pre- and post-CCRT MRIs and graded the distance between the tumor and mesorectal fascia (MRF), tumor height from the anorectal junction, tumor size, clinical TNM stage, and tumor direction. A threatened MRF was defined as the presence of a tumor within 1 mm from the MRF [5]. If a DRE result was available in the medical record, the morphology was determined by supplementing it with the endoscopic result.

All resected specimens were examined by experienced gastrointestinal pathologists. Pathological TNM stage, resection margins (such as circumferential, distal, and proximal), gross type, and lymphovascular invasion were assessed.

**Statistical analysis**

Continuous variables are expressed as mean ± standard deviation, whereas categorical variables are expressed as numbers (percentages). Univariable analyses using the Student t-test or the chi-square test were performed to identify the

| Table 1. Baseline characteristics |
|-------------------------------|
| Characteristic                  | Good response group | Poor response group | P-value |
| No. of patients                | 108                 | 339                 | 0.154   |
| Age (yr)                       | 59.0 ± 11.2         | 60.8 ± 12.0         | 0.564   |
| Sex, male:female               | 72:36               | 236:103             | 0.551   |
| Height (cm)                    | 162.61 ± 8.87       | 163.21 ± 9.26       | 0.861   |
| Weight (kg)                    | 63.93 ± 9.70        | 63.71 ± 11.54       | 0.358   |
| Body mass index (kg/cm²)       | 24.16 ± 3.02        | 23.83 ± 3.28        | 0.096   |
| ASA PS grade                   |                     |                     | 0.598   |
| I                              | 35 (27.8)           | 91 (72.2)           |         |
| II                             | 71 (23.8)           | 227 (76.2)          |         |
| III                            | 2 (8.7)             | 21 (91.3)           |         |
| Smoking                        |                     |                     | >0.999  |
| Nonsmoker                      | 58 (25.1)           | 173 (74.9)          |         |
| Ex-smoker                      | 34 (21.5)           | 124 (78.5)          |         |
| Current smoker                 | 16 (27.6)           | 42 (72.4)           |         |
| Alcohol                        | 106 (24.0)          | 335 (76.0)          |         |
| Nondrinker                     | 0 (0)               | 1 (100)             |         |
| Ex-drinker                     | 2 (40.0)            | 3 (60.0)            |         |
| Current drinker                | 10 (0)              | 76 (100)            |         |
| Diabetes mellitus              | 19 (22.9)           | 64 (77.1)           | 0.765   |
| Hypertension                   | 35 (24.1)           | 110 (75.9)          | 0.994   |
| Heart disease                  | 3 (20.0)            | 12 (80.0)           | 0.702   |
| Pulmonary disease              | 3 (37.5)            | 5 (62.5)            | 0.407   |
| Liver disease                  | 2 (14.3)            | 12 (85.7)           | 0.534   |
| Cerebral disease               | 0 (0)               | 9 (100)             | 0.122   |
| Preoperative history           | 19 (17.9)           | 87 (82.1)           | 0.092   |
| Familial cancer history        | 7 (25.9)            | 20 (74.1)           | >0.999  |
| Abnormal CEA level, >5 ng/mL   | 14 (25.9)           | 40 (74.1)           | 0.747   |
| CEA (ng/mL)                    | 3.12 ± 6.34         | 5.29 ± 24.83        | 0.370   |
| Preoperative endoscopic manage |                     |                     | 0.286   |
| None                           | 106 (23.9)          | 338 (76.1)          |         |
| Endoscopic mucosal resection   | 2 (100)             | 0 (0)               |         |
| Local excision                 | 0 (0)               | 1 (100)             |         |
| Operation                      |                     |                     | 0.002*  |
| LAR                            | 11 (22.9)           | 37 (77.1)           |         |
| Ultra LAR with double stapling | 48 (22.9)           | 162 (77.1)          |         |
| Ultra LAR with coloanal anastomosis | 28 (26.2)       | 79 (73.8)           |         |
| Abdominopereine resection      | 5 (8.9)             | 51 (91.1)           |         |
| Hartmann procedure             | 0 (0)               | 2 (100)             |         |
| Transanal local excision       | 16 (66.7)           | 8 (33.3)            |         |

Values are presented as number only, mean ± standard deviation, or number (%).
ASA, American Society of Anesthesiologists; PS, physical status; LAR, low anterior resection.
*P < 0.05.
clinical variables associated with favorable tumor response to CCRT. Multivariable analysis was performed for variables that could be examined at bedside by the clinicians before the treatment and that showed significant differences in the Student t-test and chi-square test. A correlation matrix (Spearman rho) was constructed to evaluate concordance. Multivariable analysis was then performed using a logistic regression model. Two-tailed P-values of <0.05 were considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics ver. 26 (IBM Corp., Armonk, NY, USA).

RESULTS

Baseline characteristics

Of the 447 patients (mean age, 60.37 ± 11.85 years), 108 (24.2%) achieved ypT0-1N0 post-CCRT: 77 (71.3%) with ypT0N0, 5 (4.6%) with ypTisN0, and 26 (24.1%) with ypT1N0. The patients' baseline characteristics are shown in Table 1. There

| Characteristic         | Good response group (n = 108) | Poor response group (n = 339) | P-value |
|------------------------|-------------------------------|-------------------------------|---------|
| Threatened MRF        | 54 (23.4)                     | 177 (76.6)                    | 0.740   |
| Tumor–MRF distance (mm)| 2.99 ± 4.37                   | 2.72 ± 4.54                   | 0.583   |
| Tumor heighta (mm)    | 25.84 ± 24.96                 | 26.71 ± 23.90                 | 0.752   |
| Anal verge height (cm)| 4.36 ± 2.03                   | 4.36 ± 2.15                   | 0.973   |
| Tumor size (mm)       |                               |                               |         |
| <30                    | 33 (44.0)                     | 42 (56.0)                     | <0.001* |
| ≥30                    | 75 (20.2)                     | 297 (79.8)                    |         |
| Enlarged LPN           | 31 (21.0)                     | 113 (79.0)                    | 0.290   |
| Clinical T stage      |                               |                               |         |
| T1                     | 2 (66.7)                      | 1 (33.3)                      |         |
| T2                     | 17 (48.6)                     | 18 (51.4)                     |         |
| T3                     | 80 (24.0)                     | 254 (76.0)                    |         |
| T4a                    | 7 (17.9)                      | 32 (82.1)                     |         |
| T4b                    | 2 (5.6)                       | 34 (94.4)                     |         |
| Clinical N stage      |                               |                               | 0.036*  |
| N0                     | 28 (32.9)                     | 57 (67.1)                     |         |
| N+                     | 80 (22.1)                     | 282 (77.9)                    |         |
| Enlarged LPN location |                               |                               | 0.265   |
| None                   | 78 (72.2)                     | 226 (66.7)                    |         |
| Right                  | 11 (10.2)                     | 41 (12.1)                     |         |
| Left                   | 13 (12.0)                     | 41 (12.1)                     |         |
| Bilateral             | 6 (5.6)                       | 31 (9.1)                      |         |
| Tumor direction       |                               |                               | 0.045*  |
| Anterior              | 35 (27.8)                     | 91 (72.2)                     |         |
| Posterior             | 31 (30.4)                     | 71 (69.6)                     |         |
| Lateral               | 25 (19.5)                     | 103 (80.5)                    |         |
| Encircling            | 17 (18.7)                     | 74 (81.3)                     |         |
| Endoscopic gross typeb|                               |                               | 0.003*  |
| Fungating mass        | 16 (47.1)                     | 18 (52.9)                     |         |
| Ulcerofungating mass  | 1 (10.0)                      | 9 (90.0)                      |         |
| Non-fungating mass    | 91 (22.6)                     | 312 (77.4)                    |         |
| ycT stage             |                               |                               | <0.001* |
| T0                    | 18 (66.7)                     | 9 (33.3)                      |         |
| T1                    | 6 (46.2)                      | 7 (53.8)                      |         |
| T2                    | 27 (31.4)                     | 59 (68.6)                     |         |
| T3                    | 54 (19.9)                     | 217 (80.1)                    |         |
| T4a                   | 2 (8.7)                       | 21 (91.3)                     |         |
| T4b                   | 1 (3.7)                       | 26 (96.3)                     |         |
| ycN stage             |                               |                               | 0.012*  |
| N0                    | 76 (28.8)                     | 188 (71.2)                    |         |
| N+                    | 32 (17.5)                     | 151 (82.5)                    |         |

Values are presented as number (%) or mean ± standard deviation. MRF, mesorectal fascia; LPN, lateral pelvic lymph nodes. 

*aTumor–anorectal ring distance. bIf there was a DRE result in the medical record, the morphology was determined by supplementing the endoscopic result. Non-fungating mass includes tumor types of ulcerative and infiltrative feature.

*P < 0.05.
were no significant differences in age, sex, height, weight, BMI, initial CEA level, and past medical history (including ASA PS grade, preoperative history, familial cancer history, or endoscopic procedures before treatment) between the good and poor response groups. However, transanal local excision was significantly more frequent in the good response group (66.7% vs. 33.3%, P = 0.002) (Table 1).

**Predictive factors of response to neoadjuvant concurrent chemoradiotherapy**

There were 3 patients with cT1 who received preoperative chemoradiotherapy; the clinical nodal status of all the patients before treatment was positive. Regarding cT2 disease, 16 patients with cT2N0 (8 in the good response group, 8 in the poor response group) and 19 patients with cT2N+ (9 in the good response group, 10 in the poor response group) were identified. In terms of radiological and endoscopic findings, the tumor distance to the MRF and the tumor height above the anorectal ring were not significantly associated with stage ypT0–1N0. Consequently, the proportions of patients with threatened MRF were not significantly different between the good and poor response groups. The factors associated with a good response to neoadjuvant CCRT included tumor size of <30 mm, lower clinical T and N stages before neoadjuvant CCRT, fungating tumor morphology on endoscopy, small primary tumor diameter on pretreatment MRI images, anterior/posterior directionality of the circumference, and lower ycT and ycN stages (Table 2).

Pathologically, well-differentiated tumors were also significantly associated with stage ypT0–1N0 (51.2% [22 of 43] vs. 21.3% [85 of 400] in moderately or poorly differentiated tumors, P < 0.001) (Table 3).

Table 3. Pathological characteristics

| Characteristic          | Good response group (n = 108) | Poor response group (n = 339) | P-value |
|-------------------------|-------------------------------|-------------------------------|---------|
| Histopathology          |                               |                               | 0.006*  |
| ADC, WD                 | 22 (51.2)                     | 21 (48.8)                     |         |
| ADC, MD                 | 79 (20.8)                     | 301 (79.2)                    |         |
| ADC, PD                 | 6 (30.0)                      | 14 (70.0)                     |         |
| Others                  | 1 (25.0)                      | 3 (75.0)                      |         |
| Pathological T stage    |                               |                               | <0.001* |
| T0                      | 77 (100)                      | 0 (0)                         |         |
| T1                      | 26 (78.8)                     | 7 (21.2)                      |         |
| T2                      | 0 (0)                         | 108 (100)                     |         |
| T3                      | 0 (0)                         | 211 (100)                     |         |
| T4                      | 0 (0)                         | 11 (100)                      |         |
| Tis                     | 5 (71.4)                      | 2 (28.6)                      |         |
| Pathological N stage    |                               |                               | <0.001* |
| N0                      | 92 (32.6)                     | 190 (67.4)                    |         |
| N1                      | 0 (0)                         | 112 (100)                     |         |
| N2                      | 0 (0)                         | 29 (100)                      |         |
| Nx                      | 16 (66.7)                     | 8 (33.3)                      |         |
| Tumor length (cm)       | 0.45 ± 0.83                   | 2.75 ± 1.73                   | <0.001* |
| Lymphatic invasion      | 0 (0)                         | 34 (100)                      | <0.001* |
| Venous invasion         | 0 (0)                         | 46 (100)                      | <0.001* |
| Perineural invasion     | 0 (0)                         | 109 (100)                     | <0.001* |
| Pathologic stage        |                               |                               | <0.001* |
| ypStage 0               | 79 (100)                      | 0 (0)                         |         |
| ypStage I               | 29 (24.2)                     | 91 (75.8)                     |         |
| ypStage II              | 108 (100)                     |                              |         |
| ypStage III             | 140 (100)                     |                              |         |

Values are presented as number (%) or mean ± standard deviation. ADC, adenocarcinoma; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated. *P < 0.05.

Table 4. Distribution of clinical and pathologic stages

| Clinical stage | Pathologic stage | P-value |
|----------------|------------------|---------|
|                 | ypStage 0        | ypStage I | ypStage II | ypStage III |
| cStage I        | 5 (6.3)          | 7 (5.8)   | 0 (0)      | 4 (2.9)     | <0.001*      |
| cStage II       | 16 (20.3)        | 25 (20.8) | 21 (19.4)  | 7 (5.0)     |              |
| cStage III      | 58 (73.4)        | 88 (73.3) | 87 (80.6)  | 129 (92.1)  |              |

Values are presented as number (%). *P < 0.05.

Table 5. Multivariable analysis of factors potentially associated with the good response group

| Factor                        | OR (95% CI) | P-value |
|-------------------------------|-------------|---------|
| Age (yr)                      |             |         |
| <65                           | Reference   | 0.101   |
| ≥65                           |             |         |
| Sex                           |             |         |
| Male                          | Reference   | 0.845   |
| Female                        |             |         |
| cT stage                      |             |         |
| cT1–2                         | Reference   | 0.021*  |
| cT3–4                         |             |         |
| cN stage                      |             |         |
| cN0                           | Reference   | 0.124   |
| cN+                           |             |         |
| Tumor direction               |             |         |
| Anterior/posterior            | Reference   | 0.163   |
| Lateral/encircling            |             |         |
| Histopathology                |             |         |
| ADC, WD                       | Reference   | 0.001*  |
| ADC, MD & PD                  |             |         |
| Gross type                    |             |         |
| Fungating                     | Reference   | 0.054   |
| Others                        |             |         |

Before multivariable logistic regression analyses, a correlation matrix (Spearman's rho) was constructed to evaluate concordance. Since the tumor size and clinical T stage before concurrent chemoradiotherapy have strong correlation (rho = 0.357, P < 0.001), we only selected 7 factors other than tumor size as multivariable logistic regression variables. OR, odds ratio; CI, confidence interval; ADC, adenocarcinoma; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated. *P < 0.05.
Table 5 presents the results of the multivariable logistic regression analyses. Clinical T1–2 stage (odds ratio [OR], 0.418; 95% confidence interval [CI], 0.200–0.875; P = 0.021) and well-differentiated tumors (OR, 0.313; 95% CI, 0.159–0.614; P = 0.001) were identified as independent factors associated with good response. A grossly fungating mass (OR, 0.462; 95% CI, 0.211–1.012; P = 0.054) was not significantly associated with good response on multivariable analysis.

The combined predictive value of clinical T stage (cT1–2) and tumor grade (well-differentiated type) was 50%. Thus, the combined use of these 2 factors provides information regarding tumor response to neoadjuvant CCRT in patients with rectal cancer.

**DISCUSSION**

In this study, we have identified stage cT1–2 and well differentiation of tumors as independent predictors of achieving stage ypT0–1N0 after CCRT. This finding could allow for the nonradical management of patients with middle or low rectal cancer, thus avoiding overtreatment after neoadjuvant CCRT. A fungating tumor type was just above the cutoff for significance on multivariable analysis.

To the best of our knowledge, no previous studies have been performed to predict tumor response based on achieving the ypT0–1N0 stage, which affords eligibility for transanal local excision [5]. Most previous studies have only focused on achieving a complete response [6-13]. The ability to predict stage ypT1 and pCR is important in increasing the proportion of candidates who are eligible for minimally invasive and organ-preserving surgery through local excision, which was the ultimate objective of our study.

We found that cT classification before and after CCRT, ycN classification, and tumor size on pretreatment MRI were associated with good tumor response to neoadjuvant CCRT. Moreover, cT classification was an independent predictor of stage ypT0–1N0 on multivariable analysis. A retrospective study of 23,747 patients demonstrated that cT and N classifications were correlated with pathological response after neoadjuvant CCRT [9]. Smaller tumor size has also been reported as predictor of pCR in other retrospective studies [7,26]. In our study, tumor size and clinical T stage before CCRT showed the highest degree of correlation with good outcomes. Given that tumor size and tumor stage appear to influence each other, we selected only 7 factors other than tumor size as covariates in our multivariable logistic regression model. In general, our results are consistent with those of previous studies. Data regarding tumor movability was scarce owing to the retrospective nature of our study, although tumor movability may be a surrogate for T stage [6].

The relationship between histological grade and tumor response has been evaluated in several retrospective studies involving large cohort sizes (over 20,000 participants). These studies have reported that a lower histological grade was associated with pCR [9,27]. In our study, well-differentiated tumor was associated with good tumor response and was also an independent predictor of stage ypT0–1N0 on multivariable analysis. This finding is consistent with data from previous studies [6,9].

On univariable analysis, fungating tumor morphology and an anterior/posterior direction for the circumference were associated with good tumor response; however, fungating tumor was not significantly associated with stage ypT0–1N0 on multivariable analysis. To the best of our knowledge, no previous study provides a clear explanation for the varying responses to CCRT according to a tumor’s direction or morphology. Presumably, the radiation dose may be greater in a fungating mass with a larger surface area than in a flatter mass. Studies on the characteristics of tumors, as identified by endoscopy or DRE, are few. Park et al. [6] assessed tumor movability and morphology via DRE and reported that DRE was an accurate method for predicting pCR after CCRT. They suggested that a combination of clinical, laboratory, and metabolic data would best predict pCR. However, other studies reported DRE and endoscopy as poor methods for distinguishing between postradiation fibrosis and residual cancer [28-30]. Notably, all these studies assessed tumors after CCRT to determine whether pCR was achieved but did not attempt to predict tumor response based on pretreatment gross morphology. In contrast, our study demonstrated some value for endoscopy, which was used to assess the primary tumor morphology, and reported that endoscopy is clinically important in planning treatment based on a good response to CCRT to ensure organ preservation. A prospective study is needed to verify the value of pretreatment gross morphology.

Our study has some limitations. First, the data were derived from a single institution. A multicenter study with a prospective design may provide additional reliable predictors of response to CCRT. Second, owing to the study’s retrospective nature, the data were extracted from medical charts; therefore, selection bias is inevitable. Given the finite extent of the available data, only a limited number of variables were analyzed. Although a large number of patients received neoadjuvant CCRT for rectal cancer at our center during the study period, those who did not undergo subsequent surgery were excluded. Moreover, clinical decisions were often made according to the physicians’ discretions. A prospective study may be able to evaluate additional variables that have recently received attention in the field. Even with these limitations, this is the first study evaluating the predictive factors of good response to achieve stage ypT0–1N0 which affords eligibility for transanal local excision that allows for nonradical treatment after neoadjuvant CCRT in patients with middle or low rectal cancer.
In conclusion, our study revealed that stage cT1–2 and well differentiation are predictors of stage ypT0–1N0, which in turn may provide an important and consistent indication for nonradical treatment after CCRT. Fungating tumors could be considered clinically meaningful, which may help in identifying candidates for nonradical treatment post-CCRT. These variables may also be used to stratify patients who participate in prospective studies aimed at developing new strategies for the treatment of rectal cancer.

ACKNOWLEDGEMENTS

Fund/Grant Support
None.

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo L, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835-44.
2. Lim SB, Yu CS, Hong YS, Kim TW, Park JH, Kim JH, et al. Failure patterns correlate with the tumor response after preoperative chemoradiotherapy for locally advanced rectal cancer. J Surg Oncol 2012;106:667-73.
3. Song C, Chung JH, Kang SB, Kim DW, Oh HK, Lee HS, et al. Impact of tumor regression grade as a major prognostic factor in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a proposal for a modified staging system. Cancers (Basel) 2018;10:319.
4. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240:711-8.
5. National Comprehensive Cancer Network (NCCN). Rectal cancer, version 1.2021 clinical practice guidelines in oncology [Internet]. Plymouth Meeting, PA: NCCN; c2021 [cited 2022 Feb 25]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
6. Park CH, Kim HC, Cho YB, Yun SH, Lee WY, Park YS, et al. Predicting tumor response after preoperative chemoradiation using clinical parameters in rectal cancer. World J Gastroenterol 2011;17:5310-6.
7. Garland ML, Vather R, Bunkley N, Pearse M, Bissett IP. Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Int J Colorectal Dis 2014;29:301-7.
8. Huh JW, Kim HR, Kim YJ. Clinical prediction of pathologic complete response after preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum 2013;56:698-703.
9. Al-Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol 2016;23:1177-86.
10. Yoon SM, Kim DY, Kim TH, Jung KH, Chang HJ, Koom WS, et al. Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2007;69:1167-72.
11. Rödel C, Martus P, Papadopoulos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96.
12. Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol 2006;93:145-50.
13. Lee JH, Song C, Kang SB, Lee HS, Kim JS. Predicting pathological complete regression with haematological markers during neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Anticancer Res 2018;38:6905-10.
14. Glynn-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):iv22-40.
15. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal cancer. version 2.2018. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16:874-901.

16. Heo J, Chun M, Noh OK, Oh YT, Suh KW, Park JE, et al. Sustaining blood lymphocyte count during preoperative chemoradiotherapy as a predictive marker for pathologic complete response in locally advanced rectal cancer. Cancer Res Treat 2016:48:232-9.

17. Clarke TL, White DA, Osborne ME, Shaw AM, Smart NJ, Daniels IR. Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers. Ann R Coll Surg Engl 2017;99:373-7.

18. Zhang WY, Chen XX, Chen WH, Zhang H, Zou CL. Mean corpuscular volume as a predictive factor of response to preoperative chemoradiotherapy in locally advanced rectal cancer. Gastroenterol Res Pract 2018;2018:6976375.

19. Watanabe T, Kobunai T, Akiyoshi T, Matsuda K, Ishihara S, Nozawa K. Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Dis Colon Rectum 2014;57:23-31.

20. Hur H, Tulina I, Cho MS, Min BS, Koom WS, Lim JS, et al. Biomarker-based scoring system for prediction of tumor response after preoperative chemoradiotherapy in rectal cancer by reverse transcriptase polymerase chain reaction analysis. Dis Colon Rectum 2016;59:1174-82.

21. You YN, Hardiman KM, Bafford A, Poylin V, Francone TD, Davis K, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer. Dis Colon Rectum 2020;63:1191-222.

22. Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst 2015;107:dv002.

23. Al-Husseini MJ, Saad AM, Mohamed HH, Alkhayat MA, Sonbol MB, Abdel-Rahman O. Impact of prior malignancies on outcome of colorectal cancer: revisiting clinical trial eligibility criteria. BMC Cancer 2019;19:863.

24. Kang SB, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiation (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010;11:637-45.

25. Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 2015;16:1537-46.

26. Fischer J, Eglinton TW, Frizelle FA. Clinical predictors of response to chemoradiotherapy for rectal cancer as an aid to organ preservation. ANZ J Surg 2021;91:1100-5.

27. Lorimer PD, Motz BM, Kirks RC, Boselli DM, Walsh KK, Prabhu RS, et al. Pathologic complete response rates after neoadjuvant treatment in rectal cancer: an analysis of the National Cancer Database. Ann Surg Oncol 2017;24:2095-103.

28. Guillem JG, Chessin DB, Shia J, Moore HG, Mazumdar M, Bernard B, et al. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. J Clin Oncol 2005;23:3475-9.

29. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Pate PB, Guillem JG, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002;194:131-6.

30. Song JH, Park YH, Seo SH, Lee A, Kim KH, An MS, et al. Difference in tumor area as a predictor of a pathological complete response for patients with locally advanced rectal cancer. Ann Coloproctol 2017;33:219-26.